HomeCompareRKCLF vs PFE

RKCLF vs PFE: Dividend Comparison 2026

RKCLF yields 6024.10% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RKCLF wins by $381851897045222.31M in total portfolio value
10 years
RKCLF
RKCLF
● Live price
6024.10%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$381851897045222.38M
Annual income
$369,776,937,452,127,060,000.00
Full RKCLF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — RKCLF vs PFE

📍 RKCLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRKCLFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RKCLF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RKCLF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RKCLF
Annual income on $10K today (after 15% tax)
$512,048.19/yr
After 10yr DRIP, annual income (after tax)
$314,310,396,834,307,960,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, RKCLF beats the other by $314,310,396,834,307,960,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RKCLF + PFE for your $10,000?

RKCLF: 50%PFE: 50%
100% PFE50/50100% RKCLF
Portfolio after 10yr
$190925948522611.22M
Annual income
$184,888,468,726,063,530,000.00/yr
Blended yield
96.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

RKCLF
No analyst data
Altman Z
-37.0
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RKCLF buys
0
PFE buys
0
No recent congressional trades found for RKCLF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRKCLFPFE
Forward yield6024.10%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$381851897045222.38M$49.6K
Annual income after 10y$369,776,937,452,127,060,000.00$26,258.71
Total dividends collected$381039502072311.31M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RKCLF vs PFE ($10,000, DRIP)

YearRKCLF PortfolioRKCLF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$613,110$602,409.64$9,153$693.39+$604.0KRKCLF
2$35,174,079$34,518,051.94$8,593$849.25+$35.17MRKCLF
3$1,888,383,437$1,850,747,171.74$8,336$1,066.78+$1888.38MRKCLF
4$94,881,015,458$92,860,445,181.14$8,437$1,384.80+$94881.01MRKCLF
5$4,462,021,024,330$4,360,498,337,789.21$9,013$1,875.40+$4462021.02MRKCLF
6$196,422,514,478,714$191,648,151,982,681.80$10,306$2,680.72+$196422514.47MRKCLF
7$8,094,787,458,286,058$7,884,615,367,793,833.00$12,820$4,101.38+$8094787458.27MRKCLF
8$312,337,735,848,936,300$303,676,313,268,570,240.00$17,673$6,826.70+$312337735848.92MRKCLF
9$11,285,008,965,509,618,000$10,950,807,588,151,257,000.00$27,543$12,591.86+$11285008965509.59MRKCLF
10$381,851,897,045,222,360,000$369,776,937,452,127,060,000.00$49,560$26,258.71+$381851897045222.31MRKCLF

RKCLF vs PFE: Complete Analysis 2026

RKCLFStock

Rockcliff Metals Corporation operates as a resource development and exploration company and near-term copper-zinc producer in Canada. It holds interests in various advance stage, copper, and zinc dominant volcanogenic massive sulphide deposits in the Snow Lake area of Manitoba. It holds a 100% interest in Tower property located in the Thompson Nickel Belt District in Manitoba; a 100% interest in the Rail; the Freebeth property; the Morgan property; and the Copperman property located in the Snow Lake District in Manitoba. The company is a principal landholder in the Flin Flon-Snow Lake greenstone belt, which is home to the Paleoproterozoic VMS district, hosting mines and deposits containing copper, zinc, gold, and silver. It holds an extensive portfolio of properties that totals approximately 4,000 square kilometers and include several undeveloped VMS deposits. The company was formerly known as Rockcliff Copper Corporation and changed its name to Rockcliff Metals Corporation in November 2017. Rockcliff Metals Corporation was founded in 2005 and is headquartered in Toronto, Canada.

Full RKCLF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this RKCLF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RKCLF vs SCHDRKCLF vs JEPIRKCLF vs ORKCLF vs KORKCLF vs MAINRKCLF vs JNJRKCLF vs MRKRKCLF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.